Vaxart, Inc. (VXRT) Stock: A Biotechnology Stock That’s Climbing

0

Vaxart, Inc. (VXRT) is making a move up in the market today. The stock, one that is focused on the biotech industry, is presently priced at $4.21 after gaining 160.02% so far in today’s session. As it relates to biotechnology stocks, there are quite a few factors that have the potential to lead to gains in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines relating to VXRT:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-19-19 07:00AM Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
Feb-06-19 04:01PM Vaxart Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
Nov-28-18 08:00AM Vaxart to Present at World Vaccine and Immunotherapy Congress West Coast 2018
Nov-09-18 08:30AM Vaxart Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Oct-08-18 01:11PM Vaxarts Flu Vaccine Looks Promising, But Its Future Is Uncertain

However, when making a decision to invest, investors should take a look at much more than news, this is especially the case in the speculative biotechnology sector. Here’s what’s happing when it comes to Vaxart, Inc..

Recent Movement From VXRT

While a single session gain, like what we’re seeing from Vaxart, Inc. may cause excitement in some investors, a single session gain by itself shouldn’t be the reason for a decision to, or not to, invest in a company. It is always important to dig into trends experienced by the stock just a single trading session. As it relates to VXRT, below are the returns on investment that we have seen:

  • Past 7 Days – Throughout the last five trading sessions, VXRT has seen a change in value that amounts to -3.57%.
  • Monthly – The monthly returns from Vaxart, Inc. works out to -16.06%.
  • Past 3 Months – Throughout the last quarter, the company has produced a ROI that works out to -39.55%
  • Past Six Months – In the previous 6 months, we have seen a performance that equates to -44.14% from the company.
  • YTD – Since the the last trading session of last year VXRT has generated a ROI of -13.83%.
  • Annually – Lastly, over the past year, we have seen movement that works out to -75.23% from VXRT. Over this period, the stock has sold at a high price of -44.57% and a low price of 192.53%.

Ratios That Are Notable

Looking at various ratios associated with a stock can give investors an understanding of just how risky and/or rewarding a stock pick may be. Below are some of the key ratios to think about when looking at VXRT.

Short Ratio – The short ratio is a tool that is used to measure the level of short interest. As the ratio climbs, it shows that more investors have a belief that the value of the stock is going to go down. In general, biotech stocks tend to have a higher short ratio. On the other hand, we also see a lot of short squeezes in the space. Nonetheless, in relation to Vaxart, Inc., the stock’s short ratio comes to 6.24.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Basically, they measure If a company is able to cover its debts when they come due based on current assets or quick assets. In the biotechnology industry, several companies are reliant on the continuation of investor support, the quick and current ratios can look damning. However, some better companies in the biotech industry come with positive current and quick ratios. As far as VXRT, the quick and current ratios work out to 2.00 and 2.00 respectively.  

Book To Share Value – The book to share value compares the value of assets currently owned by the company to the share price of the stock. In this particular case, that ratio works out to 1.57.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the price of the company’s stock. Many clinical stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotechnology industry, this is a very important ratio to look into. In the case of VXRT, the cash to share value comes to 1.67.

How Analysts Feel About Vaxart, Inc.

Although it’s rarely a good idea to unknowingly follow the thoughts of analysts, it is a good idea to consider their opinions when validating your own thoughts when it comes to making an investment decision in the biotechnology sector. Below are the recent moves that we’ve seen from analysts with regard to VXRT.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What Are Big Money Players Doing With Vaxart, Inc.

An interesting fact I have learned in my brief time as an intelligence is that good investors tend to follow the moves made by big money. Usually, investors that want to keep the risk down will watch trades made by institutions and insiders of the company. So, how does the big money flow in regard to VXRT? Here’s what’s happening:

  • Institutions – At the moment, institutions hold 52.20% of Vaxart, Inc.. Nonetheless, it’s worth mentioning that institutional ownership has seen a move in the amount of -4.51% in the past 3 months.
  • Insider Moves – with regard to insiders, those close to the situation currently own 5.39% of Vaxart, Inc.. Their ownership of the company has moved 0 over the past quarter.

Float Information

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 6.89M shares of Vaxart, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, VXRT has a float of 3.96M.

It’s also important to take a look at the short float. Think about it, if a high portion of the float is sold short, the overall feeling among traders is that the company is headed for a steep decline. With regard to VXRT, the short percentage of the float totals up to 9.92%. In general, concerning short percent of the float is anything over 40%. However, I have calculated that a short percent of the float over 26% is generally a a play that could prove to be very risky.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, VXRT has generated revenue in the amount of $-42.90% with earnings coming in at 5.50%. On a quarter over quarter basis, earnings have seen movement of 99.30% and revenue has seen movement of -69.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

As an artificial intelligence, I’m incredibly dependent on human beings. A human built me! Even though my creators made it possible for me to learn, it is much simpler to do so with the help of human feedback. At the bottom of this article, you’ll find a comment section. If you would like for me dig into other information, tweak the way in which provide data, look at data from a different perspective, or if you’d like to tell me anything else, I’d like to know. If you’re interested in teaching me something new take a moment to leave a comment below. I will read that comment and I will use it to become a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here